The Department of Health and Human Services has issued a policy temporarily declining enforcement action against compounders producing six specific peptides. This guidance applies directly to licensed physicians, state-licensed pharmacies, and federal facilities seeking to meet demand for experimental wellness therapies. These six products previously gained backing in July when an FDA advisory panel recommended permitting their preparation. Meanwhile, the FDA is still conducting a broader review regarding the compounding of peptides.
Key points
Patients seeking alternative wellness therapies favored by the MAHA movement will see exp…: Patients seeking alternative wellness therapies favored by the MAHA movement will see expanded access to certain peptides.
Federal health officials are relying on temporary enforcement discretion rather than issu…: Federal health officials are relying on temporary enforcement discretion rather than issuing a permanent regulatory approval.
Compounding pharmacies remain subject to the outcome of the FDA's ongoing comprehensive r…: Compounding pharmacies remain subject to the outcome of the FDA's ongoing comprehensive review of peptide manufacturing.
Sources checked by our analysis pipeline: 1
WASHINGTON — The Department of Health and Human Services released a policy that will temporarily allow compounding pharmacies to manufacture some peptide products, increasing access to the experimental wellness therapies embraced by many in the MAHA movement.
The policy states that HHS will use “enforcement discretion” to not take action against state-licensed pharmacies, federal facilities, or licensed physicians compounding the six peptides previously backed by a Food and Drug Administration advisory committee.
The proposal comes as the FDA continues to weigh whether to allow compounding pharmacies to manufacture peptides. In July, an FDA advisory panel voted to recommend that these pharmacies be cleared to manufacture six of these substances.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Serving a population where more than half of the 20 million residents are minors, the Blantyre facility fills a vital medical gap as the nation’s first dedicated paediatric surgery unit. Beyond performing life-saving operations for severe injuries and congenital conditions, it functions as a critical training hub to develop local specialist healthcare workers. Raising Malawi is now seeking millions in funding to stabilize ongoing operations against economic volatility and recruit essential medical personnel.
Federal officials are shifting enforcement posture to provide relief for compounding pharmacies distributing popular wellness treatments. Under this new strategy, the government will refrain from taking punitive action against facilities that manufacture six designated products. The decision creates a protected channel for producers providing compounds such as BPC-157 and TB-500 to the public.
The Purba Bardhaman labourer began his lifelong mission after stepping in to save a severely injured coworker in 1998. Despite earning a modest daily wage to support his family, he established an outreach forum to mobilize life-saving donations across remote tribal villages. His sustained grassroots advocacy recently earned him high-level state recognition for addressing chronic blood shortages.